Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer
about
Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data.Phenotype of circulating tumor cell: face-off between epithelial and mesenchymal masks.Epothilone B induces apoptosis and enhances apoptotic effects of ABT-737 on human cancer cells via PI3K/AKT/mTOR pathway.Chemotherapy reaction induced by ixabepilone, a microtubule stabilizing agent, mimicking extramammary Paget's disease in a patient with breast carcinoma.A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
P2860
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase II Randomized Study of I ...... or HER2-Negative Breast Cancer
@ast
Phase II Randomized Study of I ...... or HER2-Negative Breast Cancer
@en
type
label
Phase II Randomized Study of I ...... or HER2-Negative Breast Cancer
@ast
Phase II Randomized Study of I ...... or HER2-Negative Breast Cancer
@en
prefLabel
Phase II Randomized Study of I ...... or HER2-Negative Breast Cancer
@ast
Phase II Randomized Study of I ...... or HER2-Negative Breast Cancer
@en
P2093
P2860
P1476
Phase II Randomized Study of I ...... or HER2-Negative Breast Cancer
@en
P2093
Ana M Gonzalez-Angulo
Gabriel N Hortobagyi
James L Murray
Jennifer K Litton
Kimberly B Koenig
Lakshmy Nair
Majorie C Green
Nuhad K Ibrahim
Richardo H Alvarez
Savitri Krishnamurthy
P2860
P304
P356
10.1016/J.CLBC.2015.03.004
P407
P577
2015-03-24T00:00:00Z